Abstract
摘要
相似文献
1
Biosimilars.生物类似药
J Drugs Dermatol. 2014 Jul;13(7):788-90.
2
Tracking the price of existing biologics when drugs enter the market.追踪现有生物制剂在药品进入市场时的价格。
Expert Rev Pharmacoecon Outcomes Res. 2019 Aug;19(4):375-377. doi: 10.1080/14737167.2019.1630274. Epub 2019 Jun 12.
3
Are biosimilars patentable?生物类似药可获专利吗？
Expert Opin Ther Pat. 2016 Aug;26(8):871-5. doi: 10.1080/13543776.2016.1193156. Epub 2016 Jun 23.
4
Forum discusses biosimilars, better biologicals.论坛讨论生物类似药及更优质的生物制品。
Am J Health Syst Pharm. 2011 Dec 1;68(23):2210. doi: 10.2146/news110081.
5
Biosimilars: current scientific and regulatory considerations.生物类似药：当前的科学与监管考量
Curr Clin Pharmacol. 2014 Feb;9(1):53-63. doi: 10.2174/15748847113089990066.
6
A GUIDE TO FOLLOW-ON BIOLOGICS AND BIOSIMILARS WITH A FOCUS ON INSULIN.《后续生物制品和生物类似药指南：重点关注胰岛素》
Endocr Pract. 2018 Feb;24(2):195-204. doi: 10.4158/EP161728.RA.
7
Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.生物制剂和生物类似药为何仍然如此昂贵：尽管生物类似药取得了两项胜利，但最高法院最近的裁决并未解决竞争的根本障碍。
Drugs. 2018 Nov;78(17):1777-1781. doi: 10.1007/s40265-018-1009-0.
8
Biosimilars.生物类似药
Conn Med. 2015 May;79(5):295-9.
9
FDA Biosimilar Action Plan: could improving pharmacovigilance of biologics improve patient and physician confidence in biosimilars?美国食品药品监督管理局生物类似药行动计划：加强生物制品的药物警戒能否提高患者和医生对生物类似药的信心？
Expert Opin Drug Saf. 2020 Mar;19(3):229-232. doi: 10.1080/14740338.2020.1733966. Epub 2020 Mar 2.
10
Biosimilars: How Can Payers Get Long-Term Savings?生物类似药：支付方如何实现长期节省？
Pharmacoeconomics. 2016 Jun;34(6):609-16. doi: 10.1007/s40273-015-0380-x.
引用本文的文献
1
Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.应对精准医学时代高价处方药的挑战：对药物生命周期、治疗药物市场和监管框架的系统评价
PLoS One. 2017 Aug 16;12(8):e0182613. doi: 10.1371/journal.pone.0182613. eCollection 2017.
Zotero 插件